Do you want to read an article? Please log in or register.
Standard-of-Care Axicabtagene Ciloleucel for Relapsed or Refractory Large B-Cell Lymphoma: Results From the US Lymphoma CAR T Consortium
Lymphoma
Related content
Lymphoma
Lisocabtagene maraleucel for patients with relapsed or refractory large B-cell lymphomas (TRANSCEND NHL 001): a multicentre seamless design study
Lancet.
Abramson JS, Palomba ML, Gordon LI, Lunning MA, Wang M, Arnason J, Mehta A, Purev E, Maloney DG, Andreadis C, Sehgal A, Solomon SR, Ghosh N, Albertson TM, Garcia J, Kostic A, Mallaney M, Ogasawara K, Newhall K, Kim Y, Li D, Siddiqi T
doi: 10.1016/S0140-6736(20)31366-0.
COMMENTED
Lymphoma
KTE-X19 CAR T-Cell Therapy in Relapsed or Refractory Mantle-Cell Lymphoma
★ 1
Recommended by
Prof. Dr Stephan Bodis, Faculty Member
★ 2
Recommended and commented by
Prof. Dr Christoph Renner, Faculty Member
doi: 10.1056/NEJMoa1914347.
Lymphoma
Long-term safety and activity of axicabtagene ciloleucel in refractory large B-cell lymphoma (ZUMA-1): a single-arm, multicentre, phase 1-2 trial
Lancet Oncol.
Locke FL, Ghobadi A, Jacobson CA, Miklos DB, Lekakis LJ, Oluwole OO, Lin Y, Braunschweig I, Hill BT, Timmerman JM, Deol A, Reagan PM, Stiff P, Flinn IW, Farooq U, Goy A, McSweeney PA, Munoz J, Siddiqi T, Chavez JC, Herrera AF, Bartlett NL, Wiezorek JS, Navale L, Xue A, Jiang Y, Bot A, Rossi JM, Kim JJ, Go WY, Neelapu SS
doi: 10.1016/S1470-2045(18)30864-7.
Lymphoma
Tisagenlecleucel in Adult Relapsed or Refractory Diffuse Large B-Cell Lymphoma
N Engl J Med.
Schuster SJ, Bishop MR1, Tam CS, Waller EK, Borchmann P, McGuirk JP, Jäger U, Jaglowski S, Andreadis C, Westin JR, Fleury I, Bachanova V, Foley SR, Ho PJ, Mielke S, Magenau JM, Holte H, Pantano S, Pacaud LB, Awasthi R, Chu J, Anak Ö, Salles G, Maziarz RT; JULIET Investigators
doi: 10.1056/NEJMoa1804980.
Lymphoma
Selinexor in patients with relapsed or refractory diffuse large B-cell lymphoma (SADAL): a single-arm, multinational, multicentre, open-label, phase 2 trial
Lancet Haematol.
Kalakonda N, Maerevoet M, Cavallo F, Follows G, Goy A, Vermaat JSP, Casasnovas O, Hamad N, Zijlstra JM, Bakhshi S, Bouabdallah R, Choquet S, Gurion R, Hill B, Jaeger U, Sancho JM, Schuster M, Thieblemont C, De la Cruz F, Egyed M, Mishra S, Offner F, Vassilakopoulos TP, Warzocha K, McCarthy D, Ma X, Corona K, Saint-Martin JR, Chang H, Landesman Y, Joshi A, Wang H, Shah J, Shacham S, Kauffman M, Van Den Neste E, Canales MA
doi: 10.1016/S2352-3026(20)30120-4.
Lymphoma
Chimeric Antigen Receptor T Cells in Refractory B-Cell Lymphomas
N Engl J Med.
Schuster SJ, Svoboda J, Chong EA, Nasta SD, Mato AR, Anak Ö, Brogdon JL, Pruteanu-Malinici I, Bhoj V, Landsburg D, Wasik M, Levine BL, Lacey SF, Melenhorst JJ, Porter DL, June CH
doi: 10.1056/NEJMoa1708566.
Lymphoma
Tumor interferon signaling and suppressive myeloid cells associate with CAR T cell failure in large B cell lymphoma
Blood
Jain MD, Zhao H, Wang X, Atkins R, Menges M, Reid K, Spitler K, Faramand R, Bachmeier CA, Dean EA, Cao B, Chavez JC, Shah BD, Lazaryan A, Nishihori T, Hussaini MO, Gonzalez RJ, Mullinax JE, Rodriguez P, Conejo-Garcia J, Anasetti C, Davila ML, Locke FL
doi: 10.1182/blood.2020007445
Lymphoma
Single agents vs combination chemotherapy in relapsed and refractory peripheral T-cell lymphoma: Results from the comprehensive oncology measures for peripheral T-cell lymphoma treatment (COMPLETE) registry
Am J Hematol.
Stuver RN, Khan N, Schwartz M, Acosta M, Federico M, Gisselbrecht C, Horwitz SM, Lansigan F, Pinter-Brown LC, Pro B, Shustov AR, Foss FM, Jain S
doi: 10.1002/ajh.25463.
Lymphoma
The CAR T Cell Story
healthbook TIMES Oncology Hematology
Russkamp N., Zenz T.
doi: 10.36000/hbT.OH.2019.01.001